CD19 and neoplasm: In addition, CLL patients all exhibited strong infection symptoms, including the two patients with the highest proportion of CD45+/CD19+/CD235a+ cells, who died six months after undergoing CD45/CD19/CD235a testing, and one patient with approximately 30% CD45+/CD19+/CD235a+ cells, whose tumor recurred with pulmonary infection one year after CD45/CD19/CD235a testing.